H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $14 from $15 and keeps a Buy rating on the shares. The firm cites incremental dilution from the Acelyrin deal for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis and Acelyrin sign ammended merger agreement
- new option listings on April 9th
- Alumis Inc. Reports 2024 Results and Strategic Merger
- Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.
- Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreement